SurvivorNet on MSN4mon
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
Kisqali is CDK4/6 drug, which inhibit cyclin-dependent kinases, proteins that play a role in control cancer cell ...
Yahoo Finance1mon
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between ...
Hosted on MSN4mon
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
Breast cancer claims around 6,70,000 lives in a year. As per the data released by the World Health Organisation (WHO) breast cancer was the most common cancer in women in 157 countries out of 185 ...